Differential Modulation of Human M1 and M2 Macrophage Activity by ICOS-Mediated ICOSL Triggering.
ICOS:ICOSL system
anti-inflammatory activities
macrophage polarization
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
09
12
2022
revised:
26
01
2023
accepted:
31
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Activated T cells express the inducible T-cell co-stimulator (ICOS) that, upon binding to its ubiquitously expressed ligand (ICOSL), regulates the immune response and tissue repair. We sought to determine the effect of ICOS:ICOSL interaction on human M1 and M2 macrophages. M1 and M2 macrophages were polarized from monocyte-derived macrophages, and the effect of a soluble recombinant form of ICOS (ICOS-CH3) was assessed on cytokine production and cell migration. We show that ICOS-CH3 treatment increased the secretion of CCL3 and CCL4 in resting M1 and M2 cells. In LPS-treated M1 cells, ICOS-CH3 inhibited the secretion of TNF-α, IL-6, IL-10 and CCL4, while it increased that of IL-23. In contrast, M2 cells treated with LPS + IL4 displayed enhanced secretion of IL-6, IL-10, CCL3 and CCL4. In CCL7- or osteopontin-treated M1 cells, ICOS-CH3 boosted the migration rate of M1 cells while it decreased that of M2 cells. Finally, β-Pix expression was upregulated in M1 cells and downregulated in M2 cells by treatment with ICOS-CH3. These findings suggest that ICOSL activation modulates the activity of human M1 and M2 cells, thereby eliciting an overall anti-inflammatory effect consistent with its role in promoting tissue repair.
Identifiants
pubmed: 36769276
pii: ijms24032953
doi: 10.3390/ijms24032953
pmc: PMC9917690
pii:
doi:
Substances chimiques
Inducible T-Cell Co-Stimulator Protein
0
Interleukin-10
130068-27-8
Interleukin-6
0
Lipopolysaccharides
0
ICOS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 20714
Organisme : University of Turin
ID : ex 60%, DIAC_RILO_21
Organisme : European Union
ID : Horizon 2020 research and innovation program under grant agreement No 814410 (GIOTTO)
Références
J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
Cancer Immunol Immunother. 2001 Mar;50(1):51-9
pubmed: 11315510
Immunity. 2014 May 15;40(5):734-46
pubmed: 24837102
PLoS One. 2013 Oct 21;8(10):e78045
pubmed: 24205083
Cell Immunol. 2013 Jan;281(1):51-61
pubmed: 23454681
Int Immunol. 2002 Jun;14(6):555-66
pubmed: 12039907
Br J Haematol. 2022 Mar;196(6):1369-1380
pubmed: 34954822
Front Immunol. 2018 Nov 15;9:2650
pubmed: 30524429
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Cytokine. 2013 Oct;64(1):322-30
pubmed: 23778031
Int J Mol Sci. 2022 Jul 01;23(13):
pubmed: 35806368
J Immunol. 2016 Sep 15;197(6):2400-8
pubmed: 27534549
J Immunol. 2014 May 15;192(10):4921-31
pubmed: 24729612
Nat Immunol. 2009 Feb;10(2):167-75
pubmed: 19098919
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
Am J Pathol. 2011 Nov;179(5):2360-9
pubmed: 21925472
Immunology. 2011 Aug;133(4):397-408
pubmed: 21631495
Oncotarget. 2017 Dec 14;9(6):7204-7218
pubmed: 29467962
Eur J Pharmacol. 2022 Jul 5;926:175018
pubmed: 35537492
J Immunol Res. 2016;2016:9345495
pubmed: 27478856
Clin Immunol. 2005 Apr;115(1):19-25
pubmed: 15870016
J Neuroinflammation. 2014 Feb 01;11:23
pubmed: 24485070
J Immunol. 2016 Nov 15;197(10):3905-3916
pubmed: 27798154
Cell Mol Life Sci. 2009 Sep;66(18):3067-80
pubmed: 19603141
J Control Release. 2020 Apr 10;320:112-124
pubmed: 31962094
Immunol Rev. 2009 May;229(1):101-13
pubmed: 19426217
Front Immunol. 2021 Dec 03;12:786680
pubmed: 34925367
Front Immunol. 2022 Sep 02;13:992614
pubmed: 36119089
PLoS One. 2014 Apr 24;9(4):e96053
pubmed: 24763697
Eur J Immunol. 2006 Oct;36(10):2601-12
pubmed: 17013990
J Immunol. 2010 Oct 1;185(7):3970-9
pubmed: 20817864